Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01975077

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

A Randomized, Open-label Phase Ib Trial of Fruquintinib 4mg Once Daily ContinuousVersus 5mg Once Daily 3wks on/1wk Off in Patients With Metastatic Colorectal Carcinoma as 3rd Therapy

Sponsor: Fudan University

Conditions Colorectal Cancer

Interventions fruquintinib

Updated 8 times since 2017 Last updated: Feb 13, 2020 Started: Dec 31, 2012 Primary completion: Apr 30, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Colorectal Cancer and is currently completed. Fudan University leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Nov 2022 [monthly]

Completed PHASE1_PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Mar 2019 — Mar 2020 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Mar 2019 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University
Hutchison Medipharma Limited
Sun Yat-sen University

Data source: Hutchmed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China
• Shanghai, China